-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The temporal and spatial dynamics ofinterleukin (IL)-6 expression in
lymphoid organs affect the balance between antiviral humoral immunity and cellular adaptive immunity .
In particular, cytopathic viruses usually induce IL-6- mediated naive CD4+ T cells to differentiate into follicular helper T cells and promote the production of effective neutralizing antibody responses
The temporal and spatial dynamics ofinterleukin (IL)-6 expression in
SARS-CoV-2 is a cytopathic virus that can cause life-threatening pneumonia, characterized by a maladaptive inflammatory response, in which higher serum IL-6 levels are related to the severity of the disease
Methods: 30 patients with severe COVID-19 pneumonia and excessive inflammation
Results: The three groups of patients were similar in baseline demographic characteristics, laboratory test results, and respiratory parameters
.
On day 0 and day 30 , the levels of anti- RBD antibodies were similar in all groups , while on day 60 , lower but not statistically significant levels were observed in patients receiving IL-1 or IL-6 blockers.
Results: The three groups of patients were similar in baseline demographic characteristics, laboratory test results, and respiratory parameters
Conclusion: IL-1 and IL-6 inhibitors used in the treatment of severe COVID-19 patients will affect the neutralizing activity of anti- SARS-CoV-2 antibodies
Source:
Source:E.
Della-Torre, E.
E.
Della-Torre, E.
Criscuolo, M.
Lanzillotta, M.
Locatelli, N.
Clementi, N.
Mancini, L.
Dagna, IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 in patients with COVID-Antibodies 19, at the Lancet Rheumatology .
in this message
